A potent inhibitor of P-glycoprotein (ABCB1) and breast cancer resistant protein (BCRP; ABCG2).
Product Details
| Alternative Name: | N-(2-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isochinolin-2-yl)-ethyl]phenylcarbamoyl}phenyl)-3,4-dimethoxybenzamide |
| |
| Formula: | C35H37N3O6 |
| |
| MW: | 595.7 |
| |
| CAS: | 908859-10-9 |
| |
| Purity Detail: | ≥98% (TLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO, 100% ethanol or methanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. Stock solutions are stable for up to 2 months at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors: H. Muller, et al.; Bioorg. Med. Chem.
16, 2448 (2008),
Abstract;
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties: V. Jekerle, et al.; Cancer Chemother. Pharmacol.
59, 61 (2007),
Abstract;
99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides: V. Jekerle, et al.; Mol. Imaging Biol.
8, 333 (2006),
Abstract;
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques: V. Jekerle, et al.; Int. J. Cancer
119, 414 (2006),
Abstract;
